PARK7 and cancer: HER3Mab treatment showed 65% and 72% of inhibition of cancer cell growth for DJ-1 overexpressing T47-D and MCF-7 cells, respectively; while inhibition was 48% and 54%, respectively, for pcDNA T47-D and MCF-7 control cells (Figure 5B).